title: [Dose finding study of cefepime for chronic respiratory infections].
abstract: In order to determine the optimal dose of cefepime (CFPM) for respiratory tract infections, a dose finding study was conducted in patients with chronic respiratory tract infections, and the clinical properties of the drugs were compared with those of ceftazidime (CAZ). Each drug was administered by intravenous drip infusion at the dose of 2 g/day of CFPM, 4 g/day of CFPM or 2 g/day of CAZ for 14 days. 1. The overall efficacy rates evaluated by the committee were 82.6% (19/23) for the CFPM 2 g/day group, 85.0% (17/20) for the 4 g/day group and 79.3% (23/29) for the CAZ 2 g/day group, with no statistically significant difference among the three groups. 2. The overall efficacy rates evaluated by the attending physicians were 91.3% (21/23) for the CFPM 2 g/day group, 78.9% (15/19) for the CFPM 4 g/day group and 75.9% (22/29) for the CAZ 2 g/day group, with no significant difference among the three groups. 3. Bacteriological eradication rates were 88.2% (15/17) for the CFPM 2 g/day group, 68.8% (11/16) for the CFPM 4 g/day group and 63.2% (12/19) for the CAZ 2 g/day group, with no statistically significant difference among the three groups. 4. The incidences of adverse reactions were 3.8% (1/26) for the CFPM 2 g/day group, 9.1% (2/22) for the CFPM 4 g/day group and 3.4% (1/29) for the CAZ 2 g/day group, with no significant difference among the three groups. The incidences of abnormal laboratory findings were 37.5% (9/24) for the CFPM 2 g/day group, 15.0% (3/20) for the CFPM 4 g/day group and 3.4% (1/29) for the CAZ 2 g/day group. There was a significant difference among the three groups. 5. Utility rates assessed by the committee were 81.8% (18/22) for the CFPM 2 g/day group, 76.2% (16/21) for the CFPM 4 g/day group and 75.9% (22/29) for the CAZ 2 g/day group. Utility rates assessed by attending physicians were 90.9% (20/22), 78.9% (15/19) and 72.4% (21/29), respectively. There was no significant difference among the three groups. From the above results, it is concluded that the optimal dosage of CFPM is 2 g/day for chronic respiratory tract infections.
authors.affiliation: First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus.
authors.forename: A
authors.initials: A
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Shigeno
authors.forename: Y
authors.initials: Y
authors.lastname: Irabu
authors.forename: H
authors.initials: H
authors.lastname: Fukuhara
authors.forename: A
authors.initials: A
authors.lastname: Saito
authors.forename: I
authors.initials: I
authors.lastname: Nakayama
authors.forename: Y
authors.initials: Y
authors.lastname: Hiraga
authors.forename: M
authors.initials: M
authors.lastname: Ohmichi
authors.forename: K
authors.initials: K
authors.lastname: Oizumi
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects; D000077723:Cefepime; D002442:Ceftazidime / Q000008:administration & dosage / Q000494:pharmacology; D002511:Cephalosporins / Q000008:administration & dosage* / Q000494:pharmacology; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D002511:Cephalosporins; D000077723:Cefepime; D002442:Ceftazidime